J&J CEO Too Busy to Testify in Gynecomastia Trial

0
David Sell writes in the Philadelphia Inquirer about the travels and tribulations of Johnson & Johnson CEO Alex Gorsky, who will be too busy...

Profile of J&J CEO Alex Gorsky

0
1 Boring Old Man reviews the rise, and possible fall and its implication, of Johnson & Johnson CEO Alex Gorsky; who has built his...

2nd-Generation Antipsychotics Cause Extrapyramidal Side Effects as Much as 1st-Generation

7
According to researchers from Yale and the U.K., the improvements in extrapyramidal side effects expected from 2nd-generation antipsychotics has not been realized, while the...

Sales of Antipsychotics Predicted to Drop, Then Hit a High by 2021

3
After a drop to $6.5 billion in 2014, due to the loss of patent protection by the Seroquel, Zyprexa, and Abilify, sales of antipsychotics...

Texas Teen’s Lawyers Seek Testimony From J&J CEO

2
Lawyers for a Texas teenager whose lawsuit, one of 400 Johnson & Johnson faces over personal injuries caused by Risperdal, is set to begin...

J&J CEO Avoids Testimony in Philadelphia Risperdal Case

2
Chief executive Alex Gorsky was once proud enough of Risperdal to put its sales numbers on his resume, according to the Philadelphia Inquirer today,...

Risperdal Whistle-Blower Honored in Texas, Fired in Pennsylvania

2
Allen Jones, the whistle blower whose testimony resulted in a $158 million settlement by Johnson & Johnson for fraudulent marketing of Risperdal in Texas,...

Neuroleptic Drugs: Patient vs. Provider Perspective

30
In January 2012, The Journal of Social Psychiatry and Psychiatric Epidemiology published a study which suggests that providers who prescribe neuroleptics are unaware of how impacted their patients are by the adverse effects of these drugs. Now more than ever we need to reevaluate the benefits and harms that can come with psychiatric drugs. The power inherent in this kind of practice -- exercising a marginalized voice or tending to our mistakes -- is the very essence of healing.

Surgeon General Targets Rising Suicide Rate, But Not Drugs Linked to Suicide

0
An Op-Ed in Op-Ed News discusses the disconnect between concern about rising suicide rates in the general population (and the military) and awareness of...

Is the GSK Settlement Sufficient

0
An article in the New England Journal of Medicine asks whether settlements such as the $3 billion GlaxoSmithKline agreed to last July regarding off-label...

Psychotropics Drive Record 4.02 Billion U.S. Prescriptions in 2011

6
With drugs for ADHD increasing 17%, and an "unprecedented increase in patients taking antidepressants and antipsychotics," overall prescription drug sales in the United States...

Off-Label Antipsychotic Use Among Children Soaring

2
Researchers from Philadelphia and Baltimore find, in a study of Medicaid records for 50 states and the District of Columbia, that antipsychotic prescribing to...

Former FDA Counsel: J&J Settlement ‘Is Huge’

0
In an interview with Pharmalot, former FDA associate chief counsel Arnie Friede discusses the impact of last month's $181 million Risperdal settlement on pharmaceuticals'...

J&J Settles Risperdal Lawsuit on Opening Day

4
Johnson & Johnson settled one of about 420 Risperdal-related lawsuits on the trial's opening day. "The case is resolved and the client is satisfied,"...

Imagining the Fall of Antipsychotics

0
John Read and Phil Thomas imagine the eventual confession and apology by pharmaceutical companies - twenty years from now - of the harm done...

Louisiana Court Rejects J&J’s Bid to Throw Out $258 million Risperdal Award

5
The state appeals court of Lake Charles, Louisiana found that "the trial court was not manifestly erroneous in casting (Johnson & Johnson owner) Janssen...

More Evidence That Antipsychotics Shrink the Brain

27
European researchers who reviewed 43 imaging studies of first-episode psychosis found evidence that antipsychotics cause a decrease in gray matter volumes in the brain....

Neuroleptic Drugs and Violence

0
Neuroleptic Drugs and Violence by Catherine Clarke SRN, SCM, MSSCH, MBChA. and Jan Evans MCSP. Grad Dip Phys.

Low Prevalence of Obesity and Metabolic Syndrome in Never-Treated Chronic Schizophrenia

0
Research from India indicates that "schizophrenia in the absence of antipsychotic drug treatment is not a factor contributing to high prevalence of metabolic abnormalities." Abstract...

Antipsychotic Nasal Spray

0
Soulful Sepulcher takes on Alexza's new inhalable version of Loxapine, Adasuve, finding that it may cause respiratory failure. Spray Antipsychotic → 

Search Nursing Home Deficiency Reports

0
ProPublica offers an interactive tool that lets you search nursing home inspection reports for problems such as antipsychotic overprescribing.

ProPublica Offers Searchable Database of Nursing Home Inspection Reports

0
ProPublica now offers a searchable database of 20,000 nursing home inspection reports, a service which may assist in determining homes that have violated guidelines...

Antipsychotics Rise in Youth, But Hospitalization Rates Stay the Same

2
Researchers from Tufts and Harvard find in a review of 233 medical charts of psychiatrically hospitalized youth at three points in time (1991, 1998...

Antipsychotics for Childhood “Behavioral Problems” Skyrocket

4
Researchers from Columbia University and other New York institutions found a dramatically increasing use of antipsychotics to treat ADHD and other behavioral problems in...

Authors of BJP Editorial Critical of Antipsychotics Urge Reader Comment

15
The authors of a recent editorial in the British Journal of Psychiatry that urges a rethinking of the use of antipsychotics are asking that readers...